Loading clinical trials...
Loading clinical trials...
A Phase 2 Study of Cytokine-induced Memory-like NK Cells in Relapsed/Refractory AML and MDS
Conditions
Interventions
Cytokine-induced memory-like NK cells
Fludarabine
+3 more
Start Date
June 30, 2022
Primary Completion Date
December 31, 2024
Completion Date
December 31, 2024
Last Updated
March 11, 2022
NCT06303193
NCT07320235
NCT06847867
NCT06439199
NCT07216443
NCT07523555
Lead Sponsor
Washington University School of Medicine
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions